Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials

被引:0
|
作者
Bernhard Michalowsky
Wolfgang Hoffmann
Kevin Kennedy
Feng Xie
机构
[1] Site Rostock/Greifswald,German Center for Neurodegenerative Diseases (DZNE)
[2] McMaster University,Department of Health Research Methods, Evidence and Impact (Formerly Clinical Epidemiology and Biostatistics)
[3] Program for Health Economics and Outcome Measures (PHENOM),Centre for Health Economics and Policy Analysis
[4] McMaster University,Institute for Community Medicine, Section Epidemiology of Health Care and Community Health
[5] University Medicine Greifswald (UMG),undefined
来源
The European Journal of Health Economics | 2020年 / 21卷
关键词
Missing data; Multiple imputation; Cost-effectiveness analysis; Cost–utility analysis; C18; C43; I1; I10;
D O I
暂无
中图分类号
学科分类号
摘要
Outcomes in economic evaluations, such as health utilities and costs, are products of multiple variables, often requiring complete item responses to questionnaires. Therefore, missing data are very common in cost-effectiveness analyses. Multiple imputations (MI) are predominately recommended and could be made either for individual items or at the aggregate level. We, therefore, aimed to assess the precision of both MI approaches (the item imputation vs. aggregate imputation) on the cost-effectiveness results. The original data set came from a cluster-randomized, controlled trial and was used to describe the missing data pattern and compare the differences in the cost-effectiveness results between the two imputation approaches. A simulation study with different missing data scenarios generated based on a complete data set was used to assess the precision of both imputation approaches. For health utility and cost, patients more often had a partial (9% vs. 23%, respectively) rather than complete missing (4% vs. 0%). The imputation approaches differed in the cost-effectiveness results (the item imputation: − 61,079€/QALY vs. the aggregate imputation: 15,399€/QALY). Within the simulation study mean relative bias (< 5% vs. < 10%) and range of bias (< 38% vs. < 83%) to the true incremental cost and incremental QALYs were lower for the item imputation compared to the aggregate imputation. Even when 40% of data were missing, relative bias to true cost-effectiveness curves was less than 16% using the item imputation, but up to 39% for the aggregate imputation. Thus, the imputation strategies could have a significant impact on the cost-effectiveness conclusions when more than 20% of data are missing. The item imputation approach has better precision than the imputation at the aggregate level.
引用
收藏
页码:717 / 728
页数:11
相关论文
共 5 条
  • [1] Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials
    Michalowsky, Bernhard
    Hoffmann, Wolfgang
    Kennedy, Kevin
    Xie, Feng
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (05) : 717 - 728
  • [2] The Reporting of Treatment Nonadherence and Its Associated Impact on Economic Evaluations Conducted Alongside Randomized Trials: A Systematic Review
    Brilleman, Samuel L.
    Metcalfe, Chris
    Peters, Tim J.
    Hollingworth, William
    VALUE IN HEALTH, 2016, 19 (01) : 99 - 108
  • [3] Potentially missing data are considerably more frequent than definitely missing data: a methodological survey of 638 randomized controlled trials
    Kahale, Lara A.
    Diab, Batoul
    Khamis, Assem M.
    Chang, Yaping
    Lopes, Luciane Cruz
    Agarwal, Arnav
    Li, Ling
    Mustafa, Reem A.
    Koujanian, Serge
    Waziry, Reem
    Busse, Jason W.
    Dakik, Abeer
    Guyatt, Gordon
    Akl, Elie A.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2019, 106 : 18 - 31
  • [4] Is using multiple imputation better than complete case analysis for estimating a prevalence (risk) difference in randomized controlled trials when binary outcome observations are missing?
    Mavuto Mukaka
    Sarah A. White
    Dianne J. Terlouw
    Victor Mwapasa
    Linda Kalilani-Phiri
    E. Brian Faragher
    Trials, 17
  • [5] Is using multiple imputation better than complete case analysis for estimating a prevalence (risk) difference in randomized controlled trials when binary outcome observations are missing?
    Mukaka, Mavuto
    White, Sarah A.
    Terlouw, Dianne J.
    Mwapasa, Victor
    Kalilani-Phiri, Linda
    Faragher, E. Brian
    TRIALS, 2016, 17